Literature DB >> 8975609

Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans.

D Zhang1, J P Freeman, J B Sutherland, A E Walker, Y Yang, C E Cerniglia.   

Abstract

When tested as a microbial model for mammalian drug metabolism, the filamentous fungus Cunninghamella elegans metabolized chlorpromazine and methdilazine within 72 h. The metabolites were extracted by chloroform, separated by high-performance liquid chromatography, and characterized by proton nuclear magnetic resonance, mass, and UV spectroscopic analyses. The major metabolites of chlorpromazine were chlorpromazine sulfoxide (36%), N-desmethylchlorpromazine (11%), N-desmethyl-7-hydroxychlorpromazine (6%), 7-hydroxychlorpromazine sulfoxide (36%), N-hydroxychlorpromazine (11%), 7-hydroxychlorpromazine sulfoxide (5%), and chlorpromazine N-oxide (2%), all of which have been found in animal studies. The major metabolites of methdilazine were 3-hydroxymethdilazine (3%). (18)O(2) labeling experiments indicated that the oxygen atoms in methdilazine sulfoxide, methdilazine N-oxide, and 3-hydroxymethdilazine were all derived from molecular oxygen. The production of methdilazine sulfoxide and 3-hydroxymethdilazine was inhibited by the cytochrome P-450 inhibitors metyrapone and proadifen. An enzyme activity for the sulfoxidation of methdilazine was found in microsomal preparations of C. elegans. These experiments suggest that the sulfoxidation and hydroxylation of methdilazine and chlorpromazine by C. elegans are catalyzed by cytochrome P-450.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8975609      PMCID: PMC167846          DOI: 10.1128/aem.62.3.798-803.1996

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  19 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

Review 2.  Use of microorganisms for the study of drug metabolism: an update.

Authors:  A M Clark; C D Hufford
Journal:  Med Res Rev       Date:  1991-09       Impact factor: 12.944

3.  Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents.

Authors:  D Chattopadhyay; S G Dastidar; A N Chakrabarty
Journal:  Arzneimittelforschung       Date:  1988-07

4.  Metabolsm of chlorpromazine. V. Confirmation of position 7 as the major site of hydroxylation.

Authors:  H Goldenberg; V Fishman
Journal:  Biochem Biophys Res Commun       Date:  1964       Impact factor: 3.575

Review 5.  Microbial metabolism of polycyclic aromatic hydrocarbons.

Authors:  C E Cerniglia
Journal:  Adv Appl Microbiol       Date:  1984       Impact factor: 5.086

Review 6.  Mechanisms of cytochrome P-450 catalysis.

Authors:  F P Guengerich; T L MacDonald
Journal:  FASEB J       Date:  1990-05       Impact factor: 5.191

7.  Microbial models of mammalian metabolism: involvement of cytochrome P450 in the N-demethylation of N-methylcarbazole by Cunninghamella echinulata.

Authors:  W Yang; T Jiang; D Acosta; P J Davis
Journal:  Xenobiotica       Date:  1993-09       Impact factor: 1.908

8.  P450 catalysed S-oxidation of dibenzothiophene by Cunninghamella elegans.

Authors:  D Schlenk; R J Bevers; A M Vertino; C E Cerniglia
Journal:  Xenobiotica       Date:  1994-11       Impact factor: 1.908

9.  Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine.

Authors:  A N Chakrabarty; C P Bhattacharya; S G Dastidar
Journal:  APMIS       Date:  1993-06       Impact factor: 3.205

10.  Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man.

Authors:  F Hartmann; L D Gruenke; J C Craig; D M Bissell
Journal:  Drug Metab Dispos       Date:  1983 May-Jun       Impact factor: 3.922

View more
  9 in total

1.  Biotransformation of malachite green by the fungus Cunninghamella elegans.

Authors:  C J Cha; D R Doerge; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  2001-09       Impact factor: 4.792

2.  Transformation of amoxapine by Cunninghamella elegans.

Authors:  J D Moody; D Zhang; T M Heinze; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Transformation of verapamil by Cunninghamella blakesleeana.

Authors:  Lu Sun; Hai-Hua Huang; Lei Liu; Da-Fang Zhong
Journal:  Appl Environ Microbiol       Date:  2004-05       Impact factor: 4.792

5.  Fungal biotransformation of the antihistamine azatadine by Cunninghamella elegans.

Authors:  D Zhang; E B Hansen; J Deck; T M Heinze; J B Sutherland; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  1996-09       Impact factor: 4.792

Review 6.  Schizophrenia: synthetic strategies and recent advances in drug design.

Authors:  Maria Azmanova; Anaïs Pitto-Barry; Nicolas P E Barry
Journal:  Medchemcomm       Date:  2018-03-16       Impact factor: 3.597

7.  Cunninghamella as a microbiological model for metabolism of histamine H(3) receptor antagonist 1-[3-(4-tert-butylphenoxy)propyl]piperidine.

Authors:  Elżbieta Pękala; Paulina Kubowicz; Dorota Łażewska
Journal:  Appl Biochem Biotechnol       Date:  2012-09-16       Impact factor: 2.926

8.  Cadmium tolerance and removal from Cunninghamella elegans related to the polyphosphate metabolism.

Authors:  Marcos A B de Lima; Luciana de O Franco; Patrícia M de Souza; Aline E do Nascimento; Carlos A A da Silva; Rita de C C Maia; Hercília M L Rolim; Galba M C Takaki
Journal:  Int J Mol Sci       Date:  2013-03-28       Impact factor: 5.923

Review 9.  Overview on the Biochemical Potential of Filamentous Fungi to Degrade Pharmaceutical Compounds.

Authors:  Darío R Olicón-Hernández; Jesús González-López; Elisabet Aranda
Journal:  Front Microbiol       Date:  2017-09-20       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.